Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer

Hennink, Simone D.; Jong, Andrea E. van der Meulen–de; Wolterbeek, Ron; Crobach, A Stijn L P; Becx, Marco C.; Crobach, Wiet; Haastert, M. van; Hove, W. Rogier ten; Kleibeuker, Jan H.; Meijssen, M. A. C.; Nagengast, Fokko M.; Rijk, Marno C.M.; Salemans, J.M.J.I.; Stronkhorst, Arnold; Tuynman, Hans A.R.E.; Vecht, J. van der; Verhulst, M. L.; Cappel, Wouter H. de Vos tot Nederveen; H, Walinga; Weinhardt, O K; Westerveld, Dik; Witte, Ann Dryden; Wolters, H.; Cats, Annemieke; Veenendaal, R. A.; Morreau, Hans; Vasen, Hans F. A.

doi:10.1200/jco.2015.62.2035

Cited by 29 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Still, the proper interval between colonoscopies is a matter of debate,1 7 8 12–16 as is whether families with a less striking phenotype benefit from colonic surveillance 17 18…”

Section: Introductionmentioning

confidence: 99%

Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance

et al. 2016

View full text Add to dashboard Cite

The risk of CRC in Lynch families is considerable, despite biannual surveillance. We suggest less frequent and more individualised surveillance in non-Lynch families. Individuals from families with a strong history of CRC could be offered 5-year surveillance colonoscopies (unless findings at the preceding surveillance session indicate shorter interval) and individuals from moderate-risk families could be handled with the population-based screening programme for CRC after an initial surveillance colonoscopy.

show abstract

“…Still, the proper interval between colonoscopies is a matter of debate,1 7 8 12–16 as is whether families with a less striking phenotype benefit from colonic surveillance 17 18…”

Section: Introductionmentioning

confidence: 99%

Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance

et al. 2016

View full text Add to dashboard Cite

show abstract

“…There is growing evidence that five-or six-year examination intervals from the age of 45 are sufficient in most cases of FCRC [7][8][9]. Findings at the individual's first colonoscopy may also provide tools to customise future surveillance [30].…”

Section: Improving Surveillance In the Futurementioning

confidence: 99%

“…Findings at the individual's first colonoscopy may also provide tools to customise future surveillance [30]. FCRC patients with pre-malignant high-risk adenomas may have shorter intervals, and older individuals without alarming initial findings might not need continued surveillance [7,8].…”

Section: Improving Surveillance In the Futurementioning

confidence: 99%

See 1 more Smart Citation

Colonoscopic surveillance – a cost-effective method to prevent hereditary and familial colorectal cancer

Sjöström

Lindholm

Melin

2017

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Objective: Approximately 20-30% of all colorectal cancer (CRC) cases may have a familial contribution. The family history of CRC can be prominent (e.g., hereditary colorectal cancer (HCRC)) or more moderate (e.g., familial colorectal cancer (FCRC)). For family members at risk, colonoscopic surveillance is a wellestablished method to prevent both HCRC and FCRC, although the evidence for the exact procedures of the surveillance is limited. Surveillance can come at a high price if individuals are frequently examined, as this may result in unnecessary colonoscopies in relation to actual risk for CRC. This study analyses the cost-effectiveness of a surveillance programme implemented in the Northern Sweden Health Care Region. Methods: The study includes 259 individuals prospectively recorded in the colonoscopic surveillance programme registry at the Cancer Prevention Clinic, Umeå University Hospital. We performed a cost-utility analysis with a contrafactual design: we compared observed costs and loss of quality-adjusted life years (QALYs) due to CRC with the surveillance programme to an expected outcome without surveillance. The main measure was the incremental cost-effectiveness ratio (ICER) between surveillance and non-surveillance. Scenario analysis was used to explore uncertainty. Results: The ICER between surveillance and non-surveillance in the base model was 3596e/QALY. The ICER varied from À4620e in the best-case scenario to 33,779e in the worst-case scenario. Conclusion: Colonoscopic surveillance is a very cost-effective method to prevent HCRC and FCRC compared to current thresholds for cost-effectiveness and other cancer preventive interventions. ARTICLE HISTORY

show abstract

“…Hennink et al from the Netherlands recently reported results from the Familial Colorectal Cancer Surveillance (FACTS) study, which attempts to address this conundrum (9). The study is a multicenter, prospectively randomized trial evaluating colonoscopy screening intervals for people with a family history of CRC.…”

mentioning

confidence: 99%

Screening colonoscopy intervals in familial colorectal cancer

Kalady

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer

Abstract: In view of the relatively low rate of AAPs at 6 years and the absence of CRC in group A, we consider a 6-year surveillance interval appropriate. A surveillance interval of 3 years might be considered in patients with AAPs and patients with ≥ three adenomas.

Cited by 29 publications

References 33 publications

Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance

Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance

Colonoscopic surveillance – a cost-effective method to prevent hereditary and familial colorectal cancer

Screening colonoscopy intervals in familial colorectal cancer

Contact Info

Product

Resources

About